Biology may be complex, but in 2025 the industry proved it doesn’t have to be chaotic. From manufacturing CAR-T cells inside the patient to industrializing organoid platforms, the year marked a decisive move toward precision, standardization, and access, writes Priya Baraniak.
The biopharmaceutical landscape looks fundamentally different than it did just twelve months ago. For years, our industry has operated under two heavy burdens: the logistical nightmare of ex vivo cell therapy manufacturing and the predictive failure of animal models in preclinical validation. 2025 will be remembered as the year we finally decided to stop fighting these battles with brute force and started solving them with engineering.
Two distinct but parallel trends defined this year: the rapid ascent of in vivo CAR-T therapies and the industrialization of New Approach Methodologies (NAMs). While one revolutionizes how we treat patients and the other revolutionizes how we discover drugs, both represent a shift away from "bespoke biology", where process variability is accepted as a cost of doing business, toward a future of standardized, reproducible engineering.
For the last decade, the story of CAR-T has been one of miraculous efficacy tempered by logistical fragility. The "vein-to-vein" model of extracting cells, shipping them to a central facility, engineering them, and shipping them back was a triumph of science but a failure of scalability. In 2025, the paradigm shifted. We moved the manufacturing suite inside the human body.
The rise of in vivo CAR-T has fundamentally altered the conversation around Advanced Therapy Medicinal Products (ATMPs). By leveraging advancements in viral vectors and lipid nanoparticles (LNPs), we are no longer manufacturing the drug product in a cleanroom; we are manufacturing the instruction set (the vector) and allowing the patient’s own immune system to do the heavy lifting. This shifts the manufacturing burden from managing the variability of living cells to managing the precision of vector delivery. It has tremendous potential to simplify the supply chain, democratize access, and drastically reduce the cost of goods. However, it places an even higher premium on the quality of our starting materials and delivery mechanisms.
While in vivo therapies began reshaping the industry, an equally profound revolution occurred in the preclinical space. Following the passage of the FDA Modernization Act 2.0, which authorized the use of new approach methodologies (NAMs) to reduce or stop animal testing, the industry spent 2024 in a state of confusion. We knew we needed to move away from animal models, which fail to predict human responses in over 90% of cases, but we lacked the standardized tools to do so.
2025 was the year we finally acknowledged that the "reproducibility crisis" in organoids and NAMs was actually a "standardization crisis" rooted in our starting materials. For too long, organoid science has been a bespoke art, plagued by lab-specific protocols and a lack of reference standards. This year, we saw a concerted move toward the industrialization of these technologies.
As we look toward 2026, the convergence of these technologies is clear. Whether we are engineering a viral vector to reprogram T-cells in vivo or engineering an iPSC to build a liver organoid in vitro, the goal is more precise control through standardization. We are moving away from the era of "the process is the product" and entering the era where the product is the product, defined, characterized, and reproducible.
2025 taught us that biology is complex, but it doesn't have to be chaotic. By applying engineering principles to our cells and our systems, we are unlocking a future where therapies are more accessible, and drug discovery is more predictive
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.
